Medicine
Myobloc 10000 units/2 mL injection
Myobloc 10000 units/2 mL injection is a prescription medicine containing Rimabotulinumtoxinb for intramuscular use, marketed by Solstice Neurosciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store under refrigeration at 2°C to 8°C (36°F- 46°F) in the original carton to…
Key facts
- Active ingredient (INN)
- Rimabotulinumtoxinb
- Brand
- Myobloc
- Strength
- 10000 units/2 mL
- Dosage form
- Injection
- Route
- Intramuscular
- Packs
- 1 vial
- Marketing authorisation holder
- Solstice Neurosciences
- Manufacturer
- Solstice Neurosciences
- Origin register
- US FDA, United States
- Storage
- Store under refrigeration at 2°C to 8°C (36°F- 46°F) in the original carton to protect from light. DO NOT FREEZE. DO NOT SHAKE.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 December 2000
- Identifiers
- RxCUI 1736640, 1736642, 1736645 +3DailyMed set ID 675cb354-9d13-482e-8ac2-22f709c58b4fNDC 10454-710, 10454-711, 10454-712Application BLA103846
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / .5 mL in 1 vial, single-use | 10454-710-10 | Solstice Neurosciences | 1 January 2020 |
| 1 vial, single-use in 1 carton / 1 mL in 1 vial, single-use | 10454-711-10 | Solstice Neurosciences | 1 January 2020 |
| 1 vial, single-use in 1 carton / 2 mL in 1 vial, single-use | 10454-712-10 | Solstice Neurosciences | 1 January 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Rimabotulinumtoxinb is an acetylcholine release inhibitor indicated for treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults, among other approved uses. MedsAcross supplies Rimabotulinumtoxinb for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RimabotulinumtoxinbFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Myobloc prescribing information (Solstice Neurosciences) · U.S. National Library of Medicine, DailyMed
Need Myobloc 10000 units/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.